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Abstract
Dihydroartemisinin (DHA) is an important derivative of an herb medicine Artemisia annua L.,
used in ancient China. DHA is currently used world-wide to treat malaria by killing malaria-
causing parasites. In addition to this prominent effect, DHA is suggested to regulate cellular
functions, such as angiogenesis, tumor cell growth and immunity. Nonetheless, how DHA affects
T cell function remains poorly understood. We found that DHA potently suppressed Th cell
differentiation in vitro. Unexpectedly however, DHA greatly promoted Treg cell generation, in a
manner dependent on TGF-βR:Smad signal. In addition, DHA treatment effectively reduced EAE
onset and ameliorated ongoing EAE in mice. Administration of DHA significantly decreased Th
but increased Treg cells in EAE-inflicted mice without apparent global immune suppression.
Moreover, DHA modulated mTOR pathway, because mTOR signal was attenuated in T cells upon
DHA treatment. Importantly, enhanced Akt activity neutralized DHA-mediated effects on T cells
in an mTOR dependent fashion. This study therefore reveals a novel immune regulatory function
of DHA to reciprocally regulate Th and Treg cell generation through modulating mTOR pathway.
It addresses how DHA regulates immune function and suggests a new type of drug for treating
diseases where mTOR activity to be tempered.
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Introduction
Artemisinin is a sesquiterpene lactone isolated from a Chinese plant Artemisia annua
(commonly known as Qinghaosu or sweet wormwood) and has been used as a Chinese
herbal medicine for the last 2000 years to treat more than 20 different diseases including
fever (1). Since the 1970s, Artemisinin and its derivatives have been used extensively as an
anti-malaria drug by effectively killing multi-drug resistant strains of malarial parasites (2)
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through specific and selective inhibition on the SERCA of P. falciparum(3). Dihydro-
artemisinin (DHA) is the active metabolite of all artemisinin compounds (artemisinin,
artesunate, artemether, etc.) and is also an important derivative available as a drug itself.
Apart from its prominent anti-malaria effect, DHA impacts cellular functions including
tumor cell growth (4), angiogenesis (5) and immune regulation.
Aberrant function of immune system leads to the development of inflammatory and
autoimmune diseases. Immune suppressive agents are therefore needed to treat such
diseases. There have been limited amounts of research directed at the identification and
characterization of natural ingredients in plants to be used to treat inflammatory disease,
although natural plant compounds are potential sources of new classes of therapeutic agents
to control inflammation with reduced side effects. One such promising phytochemical is
Artemisinin and its derivatives. Increasing evidence suggest that artemisinin and its
derivatives possess immune suppressive function. Artemisinin was reported to effectively
relieve the symptoms of lupus nephritis in mice (6). In addition, artemisinin-derivatives
were shown to suppress delayed-type hypersensitivity response (7) and collagen-induced
arthritis (8). These findings suggest that the derivatives of artemisinin are promising agents
to modulate immune response and to treat inflammatory disease. Yet, the question of how
artemisinin or its derivative, such as DHA, impacts T cell function remains poorly
understood. More importantly, the molecular mechanisms underlying immune regulatory
function of artemisinin and its derivatives remain to be revealed. In this report, we
investigated these questions.
We found that DHA treatment modestly inhibited the proliferation of activated T cells. DHA
suppressed helper T (Th) cell function. Particularly, DHA treatment virtually abolished
Th17 differentiation. Unexpectedly however, DHA greatly promoted Treg cell generation in
a manner dependent on TGF-βR:Smad signal. These findings prompted us to test whether
DHA can be used to treat autoimmune disease. We found that DHA treatment effectively
reduced EAE onset and ameliorated ongoing EAE in mice. Administration of DHA
significantly decreased Th but increased Treg cells in EAE-inflicted mice without apparent
global immune suppression. We further investigated the molecular mechanisms underlying
DHA mediated effects on T cells and found that DHA attenuated mTOR signal in T cells.
Importantly, we found that enhanced Akt activity neutralized DHA-mediated effects on T
cells in an mTOR dependent fashion. This study therefore reveals a novel immune
regulatory function of DHA to reciprocally regulate Th17 and Treg cell generation through
modulating mTOR pathway. It addresses how DHA regulates immune function and suggests
a new type of drug for treating diseases where mTOR activity to be tempered.
Material and Methods
Mice and DHA
Wild-type (WT) and CD4cre:Smad2fl/fl mice are on C57BL/6 background and kept under
specific pathogen-free conditions in the animal care facility at the University of North
Carolina at Chapel Hill. All mouse experiments were approved by Institutional Animal Care
and Use Committee of the University of North Carolina at Chapel Hill. DHA was purchased
from Chengdu Okay Plant & Chemical Co., Ltd or TCI America with the purity of ≥98%.
For in vitro experiments, DHA was dissolved in dimethyl sulfoxide (DMSO, Sigma-
Aldrich). For in vivo injection, DHA was dissolved in the mixtures of DMSO and
polysorbate 80 (Alfa Aesar) at 6/4 (v/v) ratio.
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Cells were stained per manufactures’ protocols with fluorescence-conjugated antibodies for
CD4, CD8, CD44, IFN-γ, IL-4, CD62L, Foxp3 and IL-17A purchased from eBioscience.
For cytokines staining, cells were stimulated with 50ng/ml phorobol 12-myristate 13-acetate
(PMA) (Sigma-Aldrich) and 1μM of Ionomycin (Sigma-Aldrich) for 3–4 hours in the
presence of 2μg/ml Brefeldin A (Sigma-Aldrich) in Bruff’s medium under cell culturing
conditions (37°C, 5% CO2). Flow-cytometric analysis of antibody labeled cells was
performed on LSRII (Becton Dickinson) or CyAn (Dako Cytomation, Beckman Coulter).
The numbers of various cell populations were calculated by multiplying the total cell
number with the percentages of each cell population determined by flow-cytometry.
In vitro T cell differentiation assay
CD4+ T cells were purified by positive selection with CD4-conjugated magnetic beads
(Miltyeni Biotec). CD4+ T cells were activated by plate bound anti-CD3 and anti-CD28 in
the presence of 0.4μg/ml DHA or Mock (DMSO). TGF-β receptor I (Alk5) inhibitor
SB525334 (5mM) or mTOR inhibitor Rapamycin (5nM) was added in specific experiments
as indicated. Th cell differentiation conditions were as following. Th1: 40ng/ml rIL-12
(Peprotech) and 40μg/ml anti-IL-4 (11B11); Th2: 40ng/ml rIL-4 (Peprotech) and 10μg/ml
anti-IFN-γ (XMG); Th17: 1ng/ml rTGF-β (Preprotech), 40ng/ml rIL-6 (R&D), 40μg/ml
anti-IL-4, and 10μg/ml anti-IFN-γ; Treg: 1ng/ml rTGF-β and 2ng/ml rIL-2 (R&D).
T cell Proliferation and Apoptosis assays
For proliferation assay, CD4+ or CD8+ T cells were purified by MACS beads (Miltenyi
Biotec) and labeled with carboxyl fluorescent succinimidyl ester (CFSE, AnaSpec). Labeled
cells were stimulated with plate-bound anti-CD3 and anti-CD28 in the presence of 2ng/ml
rIL-2. After 96-hour culture, cell proliferation was assessed by CFSE dilution using flow-
cytometry. For apoptosis assay, CD4+ or CD8+ T cells were activated for indicated time.
Cells were then stained with AnnexinV-APC and 7-AAD per manufacture’s protocols (BD
Biosciences) and analyzed by flow-cytometry.
Quantitative RT-PCR and Immunoblotting assays
RNA was extracted using TRIsure reagent (Bioline) and cDNA was synthesized by Tetro
cDNA Synthesis Kit per manufacturer’s protocols (Bioline). Quantitative PCR was
performed on the ABI 7900HT Real-time PCR system using SensiMix™ II Probe Kit per
manufacturer’s protocols (Bioline) and primer/probe sets obtained from Applied Biosystems
specific for Rorc, IL-17A, IL-21, IL-23R, AhR, IL-22, IFNγ, T-bet, IL-4, GATA-3 and
HPRT. Antibodies against p-STAT3, STAT3, p-S6, S6, p-S6K, S6K, p-Smad2, Smad2/3, p-
STAT5, STAT5 (Cell Signaling Technology), RORγt (eBioscience) and β-actin (Santa Cruz
Biotechnology) were used for immunoblotting per manufacturer’s protocols.
EAE induction, prevention and treatment
Mice (12 to 16 weeks old) were immunized subcutaneously (s.c.) with 50μg of
MOG35–55peptide (MEVGWYRSPFSRVVHLYRNGK, AnaSpec) and 500μg of M.
tuberculosis (Difco) emulsified in IFA (Difco). In addition, the animals received 200ng of
Pertussis Toxin (List Biological Laboratories) intra-peritoneally (i.p.) on days 0 and 2. The
severity of EAE was monitored and graded on a clinical score of 0 to 5: 0 = no clinical
signs; 1 = Limp tail; 2 = Para-paresis (weakness, incomplete paralysis of one or two hind
limbs); 3 = Paraplegia (complete paralysis of two hind limbs); 4 = Paraplegia with forelimb
weakness or paralysis; 5 = Moribund or death. To prevent EAE development, DHA was
prepared at 10mg/ml in the 6:4 mixture of DMSO and polysorbate 80, and injected i.p. at a
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dose of 25mg/kg on day 0, and continued for 7 days. To treat ongoing EAE, DHA was
injected when mice showed clinical signs of EAE and then continued for 9 days.
Retrovirus mediated ectopic gene expression in T cells
Retroviral construct expressing a constitutive active form of AKT (caAkt) with linked
Thy1.1 marker (MSCV-IRES-Thy1.1, abbreviated as MIT) were kindly provided by Dr.
Hongbo Chi (St. Jude Children’s Research Hospital). 293 packaging cells were transfected
with retroviral constructs using FuGENE® HD transfection reagent (Roche). The
recombinant retroviruses were collected 48 and 72 h after transfection. MACS purified
CD4+ T cells were activated for 48h and then transduced with recombinant retroviruses.
Cells were cultured for additional 3 days and harvested for flow-cytometric analysis.
Statistical analysis
Data from at least three sets of samples were used for statistical analysis. Statistical
significance was calculated by Student’s t-test. A P value of less than 0.05 was considered
significant.
Results
DHA treatment suppressed T cell proliferation
To study how DHA influences T cell function, we first investigated whether DHA treatment
affected T cell activation, proliferation and survival. Under culturing conditions, DHA
showed minimal toxicity to T cells at the dose of 0.4μg/ml, although it was toxic to T cells
at high doses (>1.0μg/ml). Therefore, we used DHA at 0.4μg/ml for studies on cultured T
cells. Upon anti-CD3 and anti-CD28 stimulation, DHA did not affect T cell activation
because T cell activation markers, such as CD25, CD44 and CD69, were up-regulated
normally in DHA-treated CD4+ T cells (Fig. 1A). Nonetheless, the numbers of live CD4+ T
cells recovered from DHA-treated samples were less than those from Mock-treated samples
(Fig. 1B). To further investigate the reason for reduced T cell numbers, we assessed how
DHA treatment impacted T cell proliferation and survival. DHA treatment moderately
inhibited the proliferation of activated CD4+ T cells (Fig. 1C) without apparently affecting
cell survival (Fig. 1D). Similarly, DHA treatment marginally suppressed CD8+ T cell
proliferation but not their activation or survival (Supplementary Fig. S1). These findings
demonstrated that DHA exerts moderate inhibition on T cell proliferation without apparent
effect on T cell activation and survival.
DHA inhibited helper CD4+ T cell differentiation
CD4+ T cells are pivotal in controlling immune responses in large part by differentiating
into different types of Th cells to direct various types of immune response (9). IFN-γ
producing Th1, IL-4 producing Th2 (10–12) and IL-17A producing Th17 cells (13–15) are
the three major types of Th cells studied extensively. To test whether DHA influences Th
differentiation, CD4+ T cells were purified and cultured under Th1, Th2 or Th17 cell
skewing cytokines in the presence of DHA. We found that DHA treatment reduced IFN-γ
and IL-4 production by Th1 and Th2 cells respectively (Fig. 2A, supplementary Fig. S2A).
DHA treatment however virtually abrogated IL-17A production by differentiating Th17
cells (Fig. 2A).
Further comprehensive analysis revealed that the expression of IL-21, another Th17
promoting cytokine (16) was suppressed by DHA. In addition, the expression of IL-23R,
which promotes Th17 cells (17), was inhibited by DHA. Moreover, DHA abrogated the
expression of transcription factor retinoic-acid-related orphan receptor γ (RORγt), a master
regulator controlling Th17 differentiation (18) (Figure 2B and 2C). Nevertheless, DHA-
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mediated effects appeared to be gene specific, because the expression of certain Th17-
related genes, such as IL-22 (19) and AhR (20), were not impaired by DHA treatment
(Supplementary Fig. S2B). In addition, DHA treatment had unnoticeable effects on
phosphorylation of STAT-3, which is activated by IL-6 and critical for Th17 differentiation
(21) (Figure 2C). These findings suggest that DHA potently suppresses Th17 cell
differentiation by interfering with specific molecular programs.
DHA promoted Treg cell generation induced by TGF-β
Foxp3-expressing regulatory T (Treg) is a subset of CD4+ T cells critical to suppress
immune response (22, 23). The differentiation programs of Treg and Th17 cells antagonize
each other (24, 25): while TGF-β promotes the generation of Treg cells (26, 27), the
presence of IL-6 suppresses Treg cell generation but promotes Th17 cell generation (24, 28).
Because DHA inhibited Th17 cell differentiation (Fig. 2), we investigated if DHA affected
Treg cell generation under the same condition. Unexpectedly, the proportion of Treg cells
was greatly increased in DHA-treated cells compared to Mock-treated cells (Fig. 3A). Such
an increase was not merely due to reduced numbers of non-Treg cells (Supplementary Fig.
S2C), because the numbers of Foxp3+ Treg cells were also substantially increased (Fig. 3B).
Further investigation revealed that DHA-promoted Foxp3+ cells were indeed Treg cells,
because DHA-promoted Foxp3+ cells displayed potent immune suppressive activity in vitro
(Fig. 3C). Intrigued by this observation, we hypothesized that TGF-β-induced Treg cell
generation is promoted by DHA. Indeed, DHA treatment notably enhanced Treg cell
generation induced by TGF-β (Fig. 3D). Therefore, DHA exerted reciprocal effect on Th17
and Treg cells by inhibiting Th17 cell differentiation and promoting Treg cell generation.
TGF-βR signal is critical for Treg cell generation (29, 30). We hypothesized that DHA
regulates TGF-βR signal cascade to promote Treg cell generation. Indeed, TGF-β-induced
Smad2 activation (31), measured by its phosphorylation, was prolonged in DHA-treated
cells (Fig. 3E and 3F), although early Smad2 activation in DHA-treated cells appeared to be
comparable to Mock-treated cells (Fig. 3E and supplementary Fig. S3A). In addition, DHA
treatment did not result in a global alteration of cell signaling, because the activities of
MAPK, such as p38 and ERK, appeared normal in DHA-treated cells (Supplementary Fig.
S3B). These findings suggest that TGF-βR:Smad2 signaling cascade is important for DHA-
mediate promotion of Treg cells. To address whether TGF-βR:Smad2 signaling is required
for DHA-promoted Treg cell generation, we blocked TGF-βR function in T cells using a
pharmacological inhibitor SB525334(32) and abrogated Smad2 function using T cells from
CD4cre-Smad2fl/fl mice(33, 34), where Smad2 was deleted specifically in T cells.
Disruption of TGF-βR signal led to greatly reduced Treg generation promoted by DHA (Fig.
3G and 3H) without Th differentiation (Supplementary Fig. S3C). These results suggest that
DHA promotes Treg generation through mechanisms dependent on TGF-βR:Smad2 signal.
DHA treatment prevented the onset of EAE
The findings that DHA reciprocally regulated Th and Treg cell function promoted us to
investigate how DHA treatment may impact the development of inflammatory disease. Th17
and Th1 cells contributes to immune pathology in EAE induced by CFA-MOG injection
(35, 36), a murine model for human Multiple Sclerosis. Treg cells, on the contrary, suppress
EAE development (37). We therefore hypothesized that DHA treatment will be therapeutic
against EAE. In order to perform studies in vivo, we identified a non-toxic dose of DHA in
mice. While DHA showed noticeable toxicity at high doses (>100mg/kg), minimal toxicity
was observed when mice were injected with 25mg/kg of DHA. This dose was therefore used
for the studies performed in vivo. We first addressed whether DHA treatment was able to
prevent or to reduce the onset of EAE. When administrated daily during the first 7 days of
EAE elicitation, DHA reduced the incidence of EAE onset (Fig. 4A). In addition, the
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clinical scores of DHA-treated mice that developed EAE were much lower than those of
Mock-treated mice (Fig. 4B), suggesting that administration of DHA effectively prevented
and reduced onset of EAE in mice.
Associating with aforementioned observation, the numbers of lymphocytes infiltrating into
the spinal cord (Fig. 4C top panel) as well as Th17 and Th1 cells (Fig. 4D) were decreased
in DHA-treat mice compared to Mock-treated mice. Of note, DHA administration did not
cause systemic immune depletion or suppression, because similar numbers of splenocytes
were recovered from DHA- and Mock-treated mice (Fig. 4C lower panel) and CD4+ and
CD8+ T cells were activated equally well in DHA- and Mock-treated mice (Supplementary
Fig. S4). Thus, these findings demonstrated that DHA was effective to prevent EAE onset in
part through suppressing Th differentiation without apparently inhibiting immune function
globally.
DHA ameliorated on-going EAE
Encouraged by the above findings, we further investigated whether administration of DHA
was able to treat on-going EAE in mice. To do this, EAE was elicited in mice. When mice
developed clinical signs of EAE (limp tail), we treated them with either DHA or Mock. Over
80% of Mock-treated mice showed clinical scores above 2 and remained so (Fig. 5A and
5B). In contrast, while a large percentage of DHA-treated mice showed clinical scores above
2 during early time of treatment, majority of DHA-treated mice became less sick or disease
free at the later time (Fig. 5A and 5B) without relapse after discontinuation of DHA
treatment (data not shown). These findings suggest that DHA administration is able to
ameliorate on-going EAE and can be used to treat mice inflicted with EAE.
We further investigated whether DHA treatment affected the distribution of Th and Treg
cells in EAE-inflicted mice. The percentages of Th17 and Th1 cells were reduced in DHA-
treated mice compared with Mock-treated mice (Fig. 5C). In contrast, the percentage of Treg
cells was notably increased in DHA-treated mice compared with Mock-treated mice (Fig.
5D). Therefore, DHA treatment was effective in ameliorating ongoing EAE, associating
with reduced Th differentiation but increased Treg generation.
DHA regulates T cell function through modulating mTOR pathway
Aforementioned findings suggest that DHA is an agent effective in regulating Th and Treg
cell function to suppress immune response. We sought to further understand the molecular
mechanisms underlying DHA-mediated effects on T cells. mTOR pathway is important in
promoting Th cell function and in suppressing Treg cell function (38, 39). Inhibition of
mTOR pathway leads to defective Th cell differentiation and enhanced Treg generation, an
observation strikingly similar to DHA-mediated effects. We thus hypothesized that DHA
affected mTOR signal in T cells to reciprocally control Th and Treg cell generation. Indeed,
by assessing the phosphorylation of p70S6K and S6, indicator for the activation of mTOR
pathway (40), we found that DHA treatment reduced mTOR signaling in T cells (Fig. 6A).
In addition, cytokine IL-2 promoted mTOR activities also decreased upon DHA treatment
(Fig. 6B). Thus, DHA treatment attenuated mTOR signal.
We therefore were prompted to investigate whether mTOR signaling is functionally
involved in DHA-mediated effect. To do so, we ectopically expressed a constitutively active
form of Akt (caAkt) in T cells to enhance mTOR signal (41). The expression of caAkt
suppressed DHA-promoted Treg generation (Fig. 6C). In addition, the expression of caAkt
overcame DHA-mediated suppression of Th17 differentiation (Fig. 6D). Thus, caAkt
expression neutralized DHA-mediated effects on T cells. More importantly, the
neutralization effect of caAkt on DHA-treated T cells depended on mTOR activity, because
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addition of Rapamycin, a classic mTOR inhibitor (42), abolished caAkt-mediated effects on
DHA-treated cells (Fig. 6E). These findings suggest that the reduction of mTOR signal upon
DHA-treatment, albeit modest, is indeed functionally important for DHA-mediated effects
on T cells.
Discussion
Widely used anti-malaria drugs, artemisinin and its derivatives showed immunoregulatory
effect (6–8). Yet, the underlying mechanism remains poorly defined. In this study, we
investigated the effect of DHA, the derivative and also major metabolite of artemisinin, on T
cell function. We found that DHA suppressed Th differentiation but promoted Treg
generation, suggesting that DHA could be therapeutic to treat inflammatory disease. Indeed,
DHA treatment not only prevented the onset of EAE, but also ameliorated on-going EAE in
mouse, associating with decreased Th cells but increased Treg cells. While another
derivative of artemisinin SM933 was found suppressing EAE (8), it did not apparently affect
T cell function. Thus, subtle difference in the molecular structures of artemisinin derivatives
may result in substantial changes in their immune regulatory functions. Nonetheless, these
findings suggest that artemisinin derivative is a new class of immune regulatory agent to
suppress immune function. And DHA in particular is effective to dampen T cell function by
reciprocally controlling Th and Treg generation and to treat T cell mediated autoimmune
and inflammatory diseases.
Antigen specific and non-specific immune suppressive agents have been used to treat
inflammatory diseases. Because natural compounds generally have low side effects, studies
are needed to identify and characterize natural ingredients in plants to treat inflammatory
disease. This study identifies DHA, a derivative of a natural compound artemisinin, as an
agent that can be used for the development of antigen specific and non-specific
immunosuppressant with reduced side effects. We have found that, at effective doses, DHA
showed slight side effects on T cells in vitro and in vivo. DHA treatment only moderately
inhibited T cell proliferation without discernable effects on T cell activation or survival in
vitro. And DHA administration in vivo minimally affected animal physiology or T cell
population. At appropriate doses, DHA affected specific functions of T cells: It inhibited Th
differentiation but promoted Treg cell generation. While DHA abolished Th17
differentiation, it did not affect immediate signal of IL-6 or TGF-β and inhibited IL21/IL23-
RORγt signal axis but not IL22-Ahr signal axis. The inability of DHA to affect STAT-3
activation suggests that DHA impacts signal downstream of STAT-3. Therefore, the effect
of DHA is independent of STAT-3, but through modulating TGF-β/Smad and mTOR
pathways. The inability of DHA to affect STAT-3 function, which is critical for initiating all
Th17-associated molecular programs, could be one of the reasons for why DHA affects
certain but not all molecular programs of Th17 cells. These findings suggest that DHA could
be used as an agent to fine tune Th17 response. Therein, DHA can be used as an antigen
non-specific drug against specific T cell function and inflammation with mild side effects. In
addition, because Treg-based strategy is one of the important means to develop antigen
specific immune suppressive therapies, agent able to promote the generation and function of
Treg cells is desired for Treg-based therapy. We have found that DHA promoted Treg
generation in vitro and in vivo without substantially affecting their survival or proliferation.
It is therefore reasonable to believe that incorporation of DHA into current regimen will
enhance the efficacies of Treg-based immune therapy. Thus further studies are warranted to
explore such possibilities. Therefore, our findings suggest that DHA is a promising agent to
facilitate the development of both antigen-specific and non-specific therapies against
inflammatory diseases.
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One of the limitations of using natural product derivative to treat disease is the lack of
mechanistic understanding of their effect at the molecular levels, which contributes to the
reluctant clinical use. It is important to elucidate the molecular pathways affected by DHA.
We found that interfering with mTOR pathway is functionally critical for DHA mediated
effects in T cells because DHA treatment attenuated mTOR signal and enhanced Akt
activity corrected DHA mediated effects in T cells in a manner dependent on mTOR. We
nonetheless believe that mTOR is not the only pathway affected by DHA. DHA treatment
attenuated but not abrogated mTOR signal. In addition, our findings suggest that enhanced
Smad pathway could be another important mechanism underlying DHA mediated effect on
T cells; a mechanism that may or may not depends on mTOR signal. What additional
signaling pathways affected by DHA in mTOR dependent or independent fashion warrants
further investigation. The findings that DHA attenuated mTOR signal but enhanced Smad
signal indicate a broad application of DHA to treat diseases beyond inflammatory diseases
(e,g. cancer) where mTOR and Smad signals need to be adjusted.
While the findings in this study suggest that DHA may be beneficial to treat inflammatory
disease, it suggests the potential undesirable effect for malaria treatment where immune
suppression could be detrimental to the clearance of parasites. While DHA is effective in
clearing malaria causing parasites, DHA resistant strain do emerge to contribute to the
recrudescence of malaria. Given the observed immunosuppressive effect of DHA, the
emergency of drug resistance may be due to weakened immune function of the host. Thus,
to develop more effective malaria treatment, use of DHA in combination with immune-
enhancing agents should be considered. On the other hand, DHA-promoted Treg cell
function may benefit malaria treatment by reducing malaria-induced immune pathology,
because it has been shown that enhanced Treg cell function paradoxically prevented
experimental cerebral malaria via the function of CTLA-4 (43). Therefore, better
understanding of the mechanism of the effect of DHA on immune function is critical in
treating malaria more efficiently.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The effects of DHA on T cell activation and proliferation
1A. Purified CD4+ T cells were activated with anti-CD3 and anti-CD28 under the treatment
of DHA (solid line) and mock (dashed line) for indicated time. The expression of activation
markers CD25, CD44 and CD69 were detected by flow-cytometry. Results are
representative of at least three experiments.
1B. The numbers of CD4+ T cells recovered 4 days after activation in the presence (solid
bar) or absence (open bar) of DHA. Means ± SD of three experiments are shown. (*P<0.05)
1C. CFSE-labeled CD4+ T cells were activated with the treatment of mock (dashed line) or
DHA (solid line) for 4 days. Cell proliferation was monitored by assessing CFSE dilution by
flow-cytometry. Representative results of three experiments are shown.
1D. Purified CD4+ T cells were activated with plate bound anti-CD3 and anti-CD28 with the
treatment of Mock and DHA for 48 and 96 hours. Cells were stained with Annexin-V and 7-
AAD. The percentages of each population were detected by flow-cytometry and indicated.
Results are representation of at least three experiments.
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Figure 2. DHA inhibited helper T cell differentiation
2A. Purified CD4+ T cells were cultured under Th1, Th2, and Th17 cell polarizing
conditions with Mock or DHA treatment. IFN-γ, IL-4 and IL-17A production in CD4+ T
cells were assessed by intracellular staining and flow-cytometry. Results are representative
of at least three experiments.
2B. CD4+ T cells were cultured under Th17 cell polarizing conditions for indicated time in
the presence (solid bar) or absence (open bar) of DHA. The mRNA expression of IL-17A,
IL-21, IL-23R and Rorc was detected by qRT-PCR. Means ± SD of triplicates done in one
experiment representative of three are shown. (*P<0.05, **P<0.01)
2C. CD4+ T cells were activated under Th17 polarizing conditions in the presence (+) or
absence (−) of DHA for indicated time. The protein amounts of phosphorylated-STAT3 (p-
STAT3), STAT3, RORγt and β-actin were detected by immunoblotting. Results are
representative of three experiments. Densitometry analysis of immuno-blotting was also
shown. (N.S. Not Significant; *P<0.05)
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Figure 3. DHA promoted Treg generation through TGF-βR:Smad signaling
3A. Purified CD4+ T cells were activated under Th17 polarizing conditions for 4 days with
DHA or Mock treatment. The fractions of Foxp3 expressing Treg cells were determined by
Foxp3 intracellular staining and flow-cytometry. Means ± SD of three experiments are
shown.
3B. The total numbers of Treg cells recovered from experiments described in (A) were
compared. Means ± SD of three experiments are shown. (*P<0.05)
3C. Purified CD4+ T cells from Foxp3 reporter mice (27) were activated under Th17
polarizing conditions for 4 days with DHA treatment. Foxp3+ Treg cells were sorted and
mixed with CFSE-labeled Foxp3− naïve CD4 responder T cells (Tresp.) at different ratios.
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Cell mixtures were activated with soluble anti-CD3 in the presence of irradiated APC. Four
days post activation, the proliferative index of responder T cell was monitored by CFSE
dilution and flow-cytometry. The division index of responder T cells was determined using
FlowJo software to quantitate the degree of Treg cell-mediated suppression on the
proliferation of responder T cells. Means ± SD of three experiments are shown.
3D. CD4+ T cells were activated in the presence of varying doses of TGF-β (0–2ng/ml) with
the treatments of Mock (dashed line) or DHA (solid line) for 4 days. The percentages of
Foxp3+ Treg cells were determined by intracellular staining and flow-cytometry. Means ±
SD of triplicates done in one experiment representative of three are shown (*P<0.05).
3E. CD4+ T cells were activated under Th17 polarizing conditions with DHA (+) or Mock
(−) treatment for indicated time. The protein amounts of phosphorylated-Smad2 (p-Smad2),
Smad2 and β-actin protein were detected by immunoblotting. Results are representative of
three experiments. Densitometry analysis of immuno-blotting was also shown. (**P<0.01)
3F. CD4+ T cells were activated in the presence of 1ng/ml TGF-β with the treatment of
DHA (+) or Mock (−) for indicated time. The protein amounts of phosphorylated-Smad2 (p-
Smad2), Smad2 and β-actin protein were detected by immunoblotting. Results are
representative of three experiments. Densitometry analysis of immuno-blotting was also
shown. (**P<0.01)
3G. CD4+ T cells were activated in the presence of 1ng/ml TGF-β with the treatment of
DHA or Mock for 4 days. Cells were simultaneously treated with TGF-βRI (ALK5)
inhibitor SB525334 (+) or remain untreated (−). The fractions of Foxp3+ Treg cells were
detected by intracellular staining and flow-cytometry. Means ± SD of three experiments are
shown.
3H. CD4+ T cells were purified from wild-type (WT) or CD4cre-Smad2fl/fl mice (Smad2−)
in the presence of 1ng/ml TGF-β with the treatment of DHA or Mock for 4 days. The
fractions of Foxp3+ Treg cells were detected by intracellular staining and flow-cytometry.
Results are representative of at least three experiments. Means ± SD of three experiments
are shown.
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Figure 4. DHA treatment prevented the onset of EAE
4A. EAE was elicited in mice with MOG/CFA injection. Mice were also treated with DHA
(dashed line) or Mock (solid line) during the first 7 days of EAE elicitation. Incidence of the
mice showed clinical scores higher than 1 were recorded. Results of 12 mice in one
experiment of three are shown.
4B. As described in (A), mice were injected with MOG/CFA to elicit EAE and treated with
DHA (dashed line) or Mock (solid line). Clinical scores were recorded every day thereafter.
Mean clinical scores ± SEM of 12 mice in one experiment of three are shown (*P<0.05).
4C. As described in (A), mice were injected with MOG/CFA to elicit EAE and treated with
DHA (solid bar) or Mock (open bar). The numbers of lymphocytes infiltrating in the spinal
cord (upper panel) and total splenocytes (lower panel) in mice were counted after the
treatment. Means ± SD of six mice are shown.
4D. As described in (A), mice were injected with MOG/CFA to elicit EAE and treated with
DHA or Mock. Lymphocytes were isolated from the spinal cords and spleens of mice with
clinical score of 2. The fractions of IL-17A and IFN-γ producing CD4+ T cells were
determined by intracellular staining and flow-cytometry. Results are representative of at
least three experiments.
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Figure 5. DHA treatment ameliorated on-going EAE
5A. EAE was elicited in mice by MOG/CFA injection. When mice showed clinical signs of
EAE, they were treated either with DHA (dashed line) or with Mock (solid line) for the
following 9 days. Incidence of the mice showed clinical scores higher than 2 were recorded.
Results of 12 mice in one experiment of three are shown.
5B. As described in (A), when mice showed clinical signs of EAE, they were treated either
with DHA (dashed line) or with Mock (solid line) for the following 9 days. EAE Clinical
scores were recorded every day. Mean clinical scores ± SEM of 12 mice in one experiment
of three are shown (*P<0.05).
5C. As described in (A), when mice showed clinical signs of EAE, they were treated either
with DHA or with Mock. Lymphocytes were isolated from the spinal cords of mice with
clinical score of 2. The fractions of IL-17A and IFN-γ producing CD4+ T cells were
determined by flow-cytometry. Results are representative of at least three experiments.
5D. At the end of experiments described in (A), lymphocytes were isolated from the spinal
cords (SC), inguinal lymph-nodes (ILN), spleens and peripheral lymph-nodes (PLN) of
mice. Treg cells were identified by Foxp3 and CD25 staining. Representative result is shown
in right panel. The percentages of Foxp3+ Treg cells were determined and plotted in left
panel. Mean ± SEM of multiple mice are shown. (*P<0.05).
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Figure 6. DHA regulated T cell function by modulating mTOR pathway
6A. CD4+ T cells were activated under Th17 cell polarizing conditions for indicated time
with the treatment of DHA (+) or Mock (−). The protein amounts of phosphorylated S6 (p-
S6), S6, phosphorylated p70 S6 kinase (p-S6K), S6K and β-actin were determined by
immunoblotting. Results are representative of at least three experiments. Densitometry
analysis of immuno-blotting was also shown. (*P<0.05)
6B. Effector CD4+ T cells were stimulated in the presence of 5ng/ml IL-2 for indicated time
with the treatment of DHA (+) or Mock (−). The protein amounts of phosphorylated S6 (p-
S6), S6, phosphorylated STAT5 (p-STAT5), STAT5 and β-actin were assessed by
immunoblotting. Results are representative of at least three experiments. Densitometry
analysis of immuno-blotting was also shown. (N.S. Not Significant; *P<0.05)
6C. CD4+ T cells were activated and then transduced with control recombinant virus
MSCV-IRES-thy1.1 (MIT) or with recombinant virus expressing a constitutive active form
of Akt (MIT-caAkt) in the presence of 1ng/ml of TGF-β under the treatment of DHA
(dashed line) or Mock (solid line). Foxp3 expression in transduced (+) or un-transduced (−)
cells were assessed by intracellular staining and flow-cytometric analysis. The percentages
of Foxp3+ Treg cells were indicated above the brackets. Results are representative of three
experiments.
6D. CD4+ T cells were activated and then transduced with control recombinant virus
MSCV-IRES-thy1.1 (MIT) or with recombinant virus expressing a constitutive active form
of Akt (MIT-caAkt) under Th17 cell polarizing conditions with DHA (dashed line) or Mock
(solid line) treatment. IL-17A expression in transduced (+) or un-transduced (−) cells were
assessed by intracellular staining and flow-cytometric analysis. The percentages of IL-17A+
cells were indicated above the brackets. Results are representative of three experiments.
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6E. CD4+ T cells were activated under Th17 cell polarizing conditions with the treatment of
Mock, DHA or DHA plus Rapamycin (DHA+Rapa). Cells were transduced with control
recombinant virus MSCV-IRES-thy1.1 (MIT, solid line) or with recombinant virus
expressing a constitutive active form of Akt (MIT-caAkt, dashed line). Foxp3 and IL-17A
expression in transduced cells were assessed by intracellular staining and flow-cytometry
analysis. The percentages of Foxp3+ and IL-17A+ cells among transduced T cells are shown
above the brackets. Results are representative of three experiments.
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